|
1
|
Davies PF, Zilberberg J and Helmke BP:
Spatial microstimuli in endothelial mechanosignaling. Circ Res.
92:359–370. 2003.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Feaver RE, Gelfand BD and Blackman BR:
Human haemodynamic frequency harmonics regulate the inflammatory
phenotype of vascular endothelial cells. Nat Commun.
4(1525)2013.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Giannotta M, Trani M and Dejana E:
VE-cadherin and endothelial adherens junctions: Active guardians of
vascular integrity. Dev Cell. 26:441–454. 2013.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Gimbrone MA: The Gordon Wilson lecture.
Understanding vascular endothelium: A pilgrim's progress.
Endothelial dysfunction, biomechanical forces and the pathobiology
of atherosclerosis. Trans Am Clin Climatol Assoc. 121:115–127.
2010.PubMed/NCBI
|
|
5
|
Garcia-Cardeña G, Comander J, Anderson KR,
Blackman BR and Gimbrone MA Jr: Biomechanical activation of
vascular endothelium as a determinant of its functional phenotype.
Proc Natl Acad Sci USA. 98:4478–4485. 2001.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Ni CW, Qiu H, Rezvan A, Kwon K, Nam D, Son
DJ, Visvader JE and Jo H: Discovery of novel mechanosensitive genes
in vivo using mouse carotid artery endothelium exposed to disturbed
flow. Blood. 116:e66–e73. 2010.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Marchio P, Guerra-Ojeda S, Vila JM,
Aldasoro M, Victor VM and Mauricio MD: Targeting Early
atherosclerosis: A focus on oxidative stress and inflammation. Oxid
Med Cell Longev. 2019(8563845)2019.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Tarbell JM, Shi ZD, Dunn J and Jo H: Fluid
mechanics, arterial disease, and gene expression. Annu Rev Fluid
Mech. 46:591–614. 2014.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Chatterjee S and Fisher AB:
Mechanotransduction in the endothelium: Role of membrane proteins
and reactive oxygen species in sensing, transduction, and
transmission of the signal with altered blood flow. Antioxid Redox
Signal. 20:899–913. 2014.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Chiu JJ and Chien S: Effects of disturbed
flow on vascular endothelium: Pathophysiological basis and clinical
perspectives. Physiol Rev. 91:327–387. 2011.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Su G, Sun G, Liu H, Shu L, Zhang J, Guo L,
Huang C and Xu J: Niacin suppresses progression of atherosclerosis
by inhibiting vascular inflammation and apoptosis of vascular
smooth muscle cells. Med Sci Monit. 21:4081–4089. 2015.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Onat D, Brillon D, Colombo PC and Schmidt
AM: Human vascular endothelial cells: A model system for studying
vascular inflammation in diabetes and atherosclerosis. Curr Diab
Rep. 11:193–202. 2011.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Chen PY, Qin L, Baeyens N, Li G, Afolabi
T, Budatha M, Tellides G, Schwartz MA and Simons M:
Endothelial-to-mesenchymal transition drives atherosclerosis
progression. J Clin Invest. 125:4514–4528. 2015.PubMed/NCBI View
Article : Google Scholar
|
|
14
|
Yip SC, Saha S and Chernoff J: PTP1B: A
double agent in metabolism and oncogenesis. Trends Biochem Sci.
35:442–449. 2010.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Penafuerte C, Feldhammer M, Mills JR,
Vinette V, Pike KA, Hall A, Migon E, Karsenty G, Pelletier J,
Zogopoulos G and Tremblay ML: Downregulation of PTP1B and TC-PTP
phosphatases potentiate dendritic cell-based immunotherapy through
IL-12/IFNγ signaling. Oncoimmunology. 6(e1321185)2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Xu Q, Wu N, Li X, Guo C, Li C, Jiang B,
Wang H and Shi D: Inhibition of PTP1B blocks pancreatic cancer
progression by targeting the PKM2/AMPK/mTOC1 pathway. Cell Death
Dis. 10(874)2019.PubMed/NCBI View Article : Google Scholar
|
|
17
|
da Silva JF, Alves JV, Bolsonni JA, Costa
RM, Rios FJ, Camargo LL, Montezano AC, Touyz RM and Tostes RC:
Protein tyrosine phosphatase type 1B (PTP1B) contributes to
atherosclerotic processes by mechanisms that involve NADPH-oxidase
and calcium influx. FASEB J. 34:1. 2020.
|
|
18
|
Thompson D, Morrice N, Grant L, Le Sommer
S, Lees EK, Mody N, Wilson HM and Delibegovic M: Pharmacological
inhibition of protein tyrosine phosphatase 1B protects against
atherosclerotic plaque formation in the LDLR-/- mouse
model of atherosclerosis. Clin Sci (Lond). 131:2489–2501.
2017.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Thompson D, Morrice N, Grant L, Le Sommer
S, Ziegler K, Whitfield P, Mody N, Wilson HM and Delibegović M:
Myeloid protein tyrosine phosphatase 1B (PTP1B) deficiency protects
against atherosclerotic plaque formation in the ApoE-/-
mouse model of atherosclerosis with alterations in IL10/AMPKα
pathway. Mol Metab. 6:845–853. 2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Maupoint J, Besnier M, Gomez E, Bouhzam N,
Henry JP, Boyer O, Nicol L, Mulder P, Martinet J and Richard V:
Selective vascular endothelial protection reduces cardiac
dysfunction in chronic heart failure. Circ Heart Fail.
9(e002895)2016.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Ali MI, Ketsawatsomkron P, Belin de
Chantemele EJ, Mintz JD, Muta K, Salet C, Black SM, Tremblay ML,
Fulton DJ, Marrero MB and Stepp DW: Deletion of protein tyrosine
phosphatase 1b improves peripheral insulin resistance and vascular
function in obese, leptin-resistant mice via reduced oxidant tone.
Circ Res. 105:1013–1022. 2009.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Herren DJ, Norman JB, Anderson R, Tremblay
ML, Huby AC and Belin de Chantemèle EJ: Deletion of protein
tyrosine phosphatase 1B (PTP1B) enhances endothelial cyclooxygenase
2 expression and protects mice from type 1 diabetes-induced
endothelial dysfunction. PLoS One. 10(e0126866)2015.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Zhou H, Jiang F and Leng Y: Propofol
ameliorates ox-LDL-induced endothelial damage through enhancing
autophagy via PI3K/Akt/m-TOR pathway: A novel therapeutic strategy
in atherosclerosis. Front Mol Biosci. 8(695336)2021.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Zhang Z, Pan X, Yang S, Ma A, Wang K, Wang
Y, Li T and Liu S: miR-155 promotes ox-LDL-induced autophagy in
human umbilical vein endothelial cells. Mediators Inflamm.
2017(9174801)2017.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Shiotsugu S, Okinaga T, Habu M, Yoshiga D,
Yoshioka I, Nishihara T and Ariyoshi W: The biological effects of
interleukin-17A on adhesion molecules expression and foam cell
formation in atherosclerotic lesions. J Interferon Cytokine Res.
39:694–702. 2019.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Wang XH, Shu J, Jiang CM, Zhuang LL, Yang
WX, Zhang HW, Wang LL, Li L, Chen XQ, Jin R and Zhou GP: Mechanisms
and roles by which IRF-3 mediates the regulation of ORMDL3
transcription in respiratory syncytial virus infection. Int J
Biochem Cell Biol. 87:8–17. 2017.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Fava C and Montagnana M: Atherosclerosis
is an inflammatory disease which lacks a common anti-inflammatory
therapy: How human genetics can help to this issue. A narrative
review. Front Pharmacol. 9(55)2018.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Galkina E and Ley K: Immune and
inflammatory mechanisms of atherosclerosis (*). Annu Rev Immunol.
27:165–197. 2009.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Tousoulis D, Oikonomou E, Economou EK,
Crea F and Kaski JC: Inflammatory cytokines in atherosclerosis:
Current therapeutic approaches. Eur Heart J. 37:1723–1732.
2016.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Sun HJ, Hou B, Wang X, Zhu XX, Li KX and
Qiu LY: Endothelial dysfunction and cardiometabolic diseases: Role
of long non-coding RNAs. Life Sci. 167:6–11. 2016.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Pan JX: LncRNA H19 promotes
atherosclerosis by regulating MAPK and NF-kB signaling pathway. Eur
Rev Med Pharmacol Sci. 21:322–328. 2017.PubMed/NCBI
|
|
33
|
Watanabe T and Sato K: Roles of the
kisspeptin/GPR54 system in pathomechanisms of atherosclerosis. Nutr
Metab Cardiovasc Dis. 30:889–895. 2020.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Zhu Z, Li J and Zhang X: Salidroside
protects against ox-LDL-induced endothelial injury by enhancing
autophagy mediated by SIRT1-FoxO1 pathway. BMC Complement Altern
Med. 19(111)2019.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Gao W, Liu H, Yuan J, Wu C, Huang D, Ma Y,
Zhu J, Ma L, Guo J, Shi H, et al: Exosomes derived from mature
dendritic cells increase endothelial inflammation and
atherosclerosis via membrane TNF-α mediated NF-κB pathway. J Cell
Mol Med. 20:2318–2327. 2016.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Baudin B, Bruneel A, Bosselut N and
Vaubourdolle M: A protocol for isolation and culture of human
umbilical vein endothelial cells. Nat Protoc. 2:481–485.
2007.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Yang H, Mohamed AS and Zhou SH: Oxidized
low density lipoprotein, stem cells, and atherosclerosis. Lipids
Health Dis. 11(85)2012.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Hurtado-Roca Y, Bueno H, Fernandez-Ortiz
A, Ordovas JM, Ibañez B, Fuster V, Rodriguez-Artalejo F and
Laclaustra M: Oxidized LDL is associated with metabolic syndrome
traits independently of central obesity and insulin resistance.
Diabetes. 66:474–482. 2017.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Legeay S, Fautrat P, Norman JB, Antonova
G, Kennard S, Bruder-Nascimento T, Patel VS, Faure S and Belin de
Chantemèle EJ: Selective deficiency in endothelial PTP1B protects
from diabetes and endoplasmic reticulum stress-associated
endothelial dysfunction via preventing endothelial cell apoptosis.
Biomed Pharmacother. 127(110200)2020.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Huang T, Li X, Wang F, Lu L, Hou W, Zhu M
and Miao C: The CREB/KMT5A complex regulates PTP1B to modulate high
glucose-induced endothelial inflammatory factor levels in diabetic
nephropathy. Cell Death Dis. 12(333)2021.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Garcia-Alonso L, Iorio F, Matchan A,
Fonseca N, Jaaks P, Peat G, Pignatelli M, Falcone F, Benes CH,
Dunham I, et al: Transcription factor activities enhance markers of
drug sensitivity in cancer. Cancer Res. 78:769–780. 2018.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Bushweller JH: Targeting transcription
factors in cancer-from undruggable to reality. Nat Rev Cancer.
19:611–624. 2019.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Jha P and Das H: KLF2 in regulation of
NF-κB-mediated immune cell function and inflammation. Int J Mol
Sci. 18(2383)2017.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Zhou Z, Tang AT, Wong WY, Bamezai S,
Goddard LM, Shenkar R, Zhou S, Yang J, Wright AC, Foley M, et al:
Cerebral cavernous malformations arise from endothelial gain of
MEKK3-KLF2/4 signalling. Nature. 532:122–126. 2016.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Jiang Y and Shen Q: IRF2BP2 prevents
ox-LDL-induced inflammation and EMT in endothelial cells via
regulation of KLF2. Exp Ther Med. 21(481)2021.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Li Q, Xuan W, Jia Z, Li H, Li M, Liang X
and Su D: HRD1 prevents atherosclerosis-mediated endothelial cell
apoptosis by promoting LOX-1 degradation. Cell Cycle. 19:1466–1477.
2020.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Patel R, Varghese JF, Singh RP and Yadav
UCS: Induction of endothelial dysfunction by oxidized low-density
lipoproteins via downregulation of Erk-5/Mef2c/KLF2 signaling:
Amelioration by fisetin. Biochimie. 163:152–162. 2019.PubMed/NCBI View Article : Google Scholar
|
